Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzodiazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzodiazepine SCHEMBL28096295 | 0.91 | GAA (0.38) | GAAMAPT | |
| Benzodiazepine SCHEMBL8137 | 0.89 | GAA (0.44) | GAAMAPT | |
| Benzodiazepine SCHEMBL7160172 | 0.89 | GAA (0.44) | GAAMAPT | |
| Benzodiazepine SCHEMBL27883058 | 0.87 | GAA (0.40) | GAAMAPT | |
| Benzodiazepine SCHEMBL22578992 | 0.87 | MAPT (0.33) | GAAMAPT | |
| Benzodiazepine SCHEMBL11809777 | 0.87 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL11474576 | 0.87 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL4700331 | 0.87 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL4420872 | 0.87 | GAA (0.43) | GAAMAPT | |
| Benzodiazepine SCHEMBL11484022 | 0.87 | GAA (0.43) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105203623-B | The dizzy application as MALDI-TOF MS substrate in little Molecular Detection of six tert-butyl groups-six hexyloxy-six benzo [ab, de, lm, op, rs, uv] | 陕西师范大学 | 2016-07-27 | — | — | CN | disclosed |
| WO-2016115282-A1 | BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-2564851-B1 | Agent exhibiting the properties of a cognitive function promoter | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU UNIKORM (RU) | 2014-06-11 | — | — | EP | disclosed |
| US-8476433-B2 | Agent exhibiting the properties of a cognitive function promoter (embodiments) | UNIKORM (RU) | 2013-07-02 | — | — | US | disclosed |
| US-20130131342-A1 | AGENT EXHIBITING THE PROPERTIES OF A COGNITIVE FUNCTION PROMOTER (EMBODIMENTS) | UNIKORM (RU) | 2013-05-23 | — | — | US | disclosed |
| EP-2564851-A2 | AGENT EXHIBITING THE PROPERTIES OF A COGNITIVE FUNCTION PROMOTER (EMBODIMENTS) | Obschestvo S Ogranichennoi Otvetstvennostju "Unikorm" (RU) | 2013-03-06 | — | — | EP | disclosed |
| EP-2419106-A1 | BENZODIAZEPINE DERIVATIVE FOR THE TREATMENT OF HEMATOPOIETIC NEOPLASM AND LEUKEMIA | Eli Lilly and Company (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2370439-A1 | LACTAMS AS BETA SECRETASE INHIBITORS | Pfizer Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011080758-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED QUINOXALINES | ALKEM LABORATORIES LTD. (IN) | 2011-07-07 | — | — | WO | disclosed |
| WO-2010120614-A1 | BENZODIAZEPINE DERIVATIVE FOR THE TREATMENT OF HEMATOPOIETIC NEOPLASM AND LEUKEMIA | ELI LILLY AND COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010058333-A1 | LACTAMS AS BETA SECRETASE INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-2173348-A2 | POTENTIATION OF CANCER CHEMOTHERAPY | Eli Lilly & Company (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009006043-A2 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2,5-DIHYDRO-4-IMIDAZO [1,2-A]PYRINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO-2-(1-PIPERIDINYL-CARBONYD-PYRROLO[3,2,1-JK][1,4]BENZODIAZEPINE | ELI LILLY AND COMPANY (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2007002359-A2 | METHODS FOR IDENTIFYING DELTA SUBUNIT-CONTAINING GABA RECEPTOR MODULATORY AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131342-A1 | AGENT EXHIBITING THE PROPERTIES OF A COGNITIVE FUNCTION PROMOTER (EMBODIMENTS) | BDNF, TET1, PNMT | GAA 2711/4885MAPT 1014/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | GAA 44/4885MAPT 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.